

Maklumat tambahan indikasi untuk upload pada laman web

Year 2012

Products Approved For Additional Indication (DCA 257 – 23 Oktober 2012)

NO	PRODUCT (ACTIVE INGREDIENT)	ADDITIONAL INDICATION	MARKETING AUTHORIZATION HOLDER
1.	<p>1.1 Herceptin Vial 440 Mg Powder For Concentrate [Trastuzumab 440 mg/vial]</p> <p>1.2 Herceptin Vial 150 Mg Powder For Concentrate [Trastuzumab 150 mg/vial]</p> <p>1.3 Herceptin Vial 150 Mg Powder For Concentrate For Solution For Infusion [Trastuzumab 150 mg/vial]</p>	<p>➤ Indication:</p> <p><i>Herceptin is indicated for the treatment of patients with HER2 positive early breast cancer:</i></p> <ul style="list-style-type: none"><i>• in combination with neoadjuvant chemotherapy followed by adjuvant Herceptin, for locally advanced (including inflammatory) breast cancer or tumours > 2 cm in diameter.</i>	<p>ROCHE (M) SDN BHD Level 56- 58, Vista Tower, The Intermark, 182, Jalan Tun Razak, 50400 Kuala Lumpur.</p>